Tetra Bio-Pharma and Ovensa Will Engage in a Collaboration to Tackle Brain Cancer
April 11 2019 - 6:30AM
Tetra Bio-Pharma Inc. ("
Tetra" or
the "
Company") (TSX-V: TBP) (OTCQB: TBPMF),
today announced that it has entered into a collaboration agreement
with Ovensa Inc. ("Ovensa") to evaluate TRIOZAN™, a proprietary
nanomedicine platform for targeted delivery of cannabinoids to
brain tumor cells.
"Glioblastoma multiforme (GBM) is a common and
fatal type of brain cancer and sadly took the lives of Senator John
McCain and singer Gordon Downey. Our collaboration with Ovensa will
evaluate if TRIOZANÔ allows a targeted delivery of cannabinoids to
the brain tumor. There is some published evidence
demonstrating the activity of cannabinoids on brain tumors.
If successful this could provide an increased efficacy when this
treatment is used as an adjunct to radiotherapy and or
chemotherapy. This technology is also being investigated for the
delivery of an antibody to the brain as part of a collaboration
between Ovensa and Takeda Pharmaceutical. Our collaboration with
Ovensa is part of our ongoing cancer research program,” said Dr.
Guy Chamberland, CEO and CSO of Tetra Bio-Pharma.
‘’Ovensa’s TRIOZANTM Delivery Platform allows a
high engineering flexibility where personalized nanomedicines are
designed according to various parameters such as pathology, gene
and molecular profile, cell targeting, type of payload, route of
administration and multi-combination. The current collaboration is
aimed at engineering a targeted Glioblastoma Dual-Cannabinoid
TRIOZANTM-based therapeutic to achieve synergistic effects with
therapeutic tools such as chemotherapy, radiotherapy and
immunotherapy”, said Ovensa's President and CEO, Mr. Stéphane
Gagné.
About Glioblastoma Multiforme (Brain
Cancer)Glioblastoma multiforme (GBM) is the most common
and most malignant of the glial tumors with a 5-year survival rate
lower than 5%. Its incidence in most European and North American
countries is approximately 2-3 new cases per 100,000 people per
year. The tremendous unmet need in GBM is substantiated by the lack
of treatment progress and improvement in overall survival in this
indication over the last several years.
About Ovensa IncOvensa is a
preclinical stage company fighting inherent therapeutic resistance
in complex diseases by generating advanced nanotherapeutics using
its proprietary TRIOZAN™ Delivery Platform. The company focuses on
advancing its lead drug candidates as well as generating novel
nanotherapeutic candidates in collaboration with pharmaceutical
companies for applications in CNS and immuno-oncology. For more
information visit: www.ovensa.com
About Tetra Bio-Pharma:Tetra Bio-Pharma
(TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in
cannabinoid-based drug discovery and development with a Health
Canada authorized, and FDA reviewed, clinical trials aimed at
bringing novel prescription drugs and treatments to patients and
their healthcare providers. The Company has several subsidiaries
engaged in the development of an advanced and growing pipeline of
Bio Pharmaceuticals, Natural Health and Veterinary Products
containing cannabis and other medicinal plant-based elements. With
patients at the core of what we do, Tetra Bio-Pharma is focused on
providing rigorous scientific validation and safety data required
for inclusion into the existing bio pharma industry by regulators,
physicians and insurance companies. For more information visit:
www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain
forward-looking information. All statements, other than of
historical fact, that address activities, events or developments
that the Company believes, expects or anticipates will or may occur
in the future (including, without limitation, statements regarding
potential acquisitions and financings) are forward-looking
statements. Forward-looking statements are generally identifiable
by use of the words "may", "will", "should", "continue", "expect",
"anticipate", "estimate", "believe", "intend", "plan" or "project"
or the negative of these words or other variations on these words
or comparable terminology. Forward-looking statements are subject
to a number of risks and uncertainties, many of which are beyond
the Company's ability to control or predict, that may cause the
actual results of the Company to differ materially from those
discussed in the forward-looking statements. Factors that could
cause actual results or events to differ materially from current
expectations include, among other things, without limitation, the
inability of the Company to obtain sufficient financing to execute
the Company's business plan; competition; regulation and
anticipated and unanticipated costs and delays, the success of the
Company's research and development strategies, including the
success of CAUMZ and its other drug candidates, the applicability
of the discoveries made therein, the successful and timely
completion and uncertainties related to the regulatory process
including the applications for Orphan Drug Designation, the timing
of clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news
release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
Tetra Bio-Pharma Contact |
Ovensa Inc. Contact |
Steeve Neron |
Stéphane Gagné |
Sr. Vice-President |
President and CEO |
Marketing and Medical
Affairs |
905-726-9933 |
sneron@tetrabiopharma.com |
sgagne@ovensa.com |
|
|
Investor Contact: |
|
Maison Brisson |
|
Pierre Boucher, CPA, CMA |
|
Partner, Executive Vice-President |
|
514-731-0000 ext. 237 |
|
Investors@tetrabiopharma.com |
|
|
|
Media Contact : |
|
Energi PR |
|
Carol Levine, APR, FCPRS |
|
514-288-8500 ext. 226 |
|
Carol.levine@energipr.com |
|
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Apr 2023 to Apr 2024